<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00263471</url>
  </required_header>
  <id_info>
    <org_study_id>2612-2320</org_study_id>
    <nct_id>NCT00263471</nct_id>
  </id_info>
  <brief_title>Myopia Progression and the Effect of 7-Methylxanthine</brief_title>
  <official_title>Phase 2 Study of the Effect of 7-Methylxanthine on the Progression of Childhood Myopia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Trier Research Laboratories</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Generalkonsul Einar Høyvalds Fond</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Jørgen Bagenkop Nielsens Myopi-Fond</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Chr. Andersen og hustru Ingeborg Andersen, f. Schmidts legat (fond) oprettet af deres datter, frk. Lilli Ellen Andersen.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Trier Research Laboratories</source>
  <brief_summary>
    <textblock>
      7-methylxanthine has been shown to increase the concentration and thickness of collagen
      fibrils in rabbit sclera. Deficient collagen in the sclera may be the cause of progression of
      childhood myopia. The study hypothesis is that treatment with 7-methylxanthine will stabilize
      the sclera and prevent further progression of myopia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Participants are given tablets of 7-methylxanthine 400 mg per day or placebo tablets for 12
      months. Axial length, cycloplegic refraction and corneal curvature is measured, as well as
      weight, height, blood pressure and heart rate. The participants are interviewed about
      possible CNS, gastrointestinal, or cardiopulmonal side effects.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>October 2003</start_date>
  <completion_date>March 2006</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Axial growth</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Myopia progression</measure>
  </secondary_outcome>
  <enrollment>90</enrollment>
  <condition>Myopia</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>7-methylxanthine</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Children in the age 8-13 years with myopia and an axial growth rate of 0.15 mm or more per
        year.

        Exclusion Criteria:

        Severe general ailment (for example diabetes, epilepsy, psychiatric disease) Eye diseases
        (for example cataract, keratoconus, chronic iritis, glaucoma)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>8 Years</minimum_age>
    <maximum_age>13 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Klaus Trier, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Trier Research Laboratories</affiliation>
  </overall_official>
  <reference>
    <citation>Trier K, Olsen EB, Kobayashi T, Ribel-Madsen SM. Biochemical and ultrastructural changes in rabbit sclera after treatment with 7-methylxanthine, theobromine, acetazolamide, or L-ornithine. Br J Ophthalmol. 1999 Dec;83(12):1370-5.</citation>
    <PMID>10574816</PMID>
  </reference>
  <verification_date>October 2003</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 6, 2005</study_first_submitted>
  <study_first_submitted_qc>December 6, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 8, 2005</study_first_posted>
  <last_update_submitted>December 13, 2005</last_update_submitted>
  <last_update_submitted_qc>December 13, 2005</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 14, 2005</last_update_posted>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myopia</mesh_term>
  </condition_browse>
  <pending_results>
    <submitted>September 21, 2009</submitted>
    <returned>October 20, 2009</returned>
    <submitted>October 22, 2009</submitted>
    <returned>November 24, 2009</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

